Drug Profile
VK 2809
Alternative Names: MB-07811; VK-2809Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Metabasis Therapeutics
- Developer Duke University; Viking Therapeutics
- Class Antihyperlipidaemics; Obesity therapies; Organophosphorus compounds; Small molecules
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypercholesterolaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- No development reported Adrenoleucodystrophy; Glycogen storage disease type I
Most Recent Events
- 10 Nov 2023 Efficacy and adverse events data from phase II VOYAGE trial in Non alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 16 May 2023 Efficacy and adverse events data from phase II VOYAGE trial in Non alcoholic steatohepatitis were released by Ligand Pharmaceuticals
- 16 May 2023 Efficacy and adverse events data from phase II VOYAGE trial in Non alcoholic steatohepatitis were released by Ligand Pharmaceuticals